AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9800
0.0000 (0.0000%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9800
Open0.9807
Bid0.9600 x 1000
Ask1.0400 x 3000
Day's Range0.9597 - 0.9950
52 Week Range0.9000 - 5.1700
Volume407,196
Avg. Volume499,849
Market Cap8.72M
Beta2.83
PE Ratio (TTM)-1.13
EPS (TTM)-0.87
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical

    LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for iBio, Inc. (NYSE: IBIO ), following which we have published a ...

  • PR Newswire4 days ago

    Aethlon Medical Announces Large-Scale Production Collaboration

    SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®.  iBio is a leading developer of plant-based biopharmaceuticals. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

  • GlobeNewswire4 days ago

    iBio Announces Manufacturing Collaboration with Aethlon Medical

    NEW YORK, Oct. 16, 2017-- iBio, Inc., a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the establishment of an agreement with Aethlon Medical, ...

  • How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?
    Simply Wall St.8 days ago

    How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?

    Aethlon Medical Inc (NASDAQ:AEMD), a USD$14.64M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • PR Newswire9 days ago

    Aethlon Medical to Present at the 2017 BIO Investor Forum

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 2017 BIO Investor Forum in San Francisco, CA on October 18, 2017, at 2:15pm (pacific time) at the Westin St. Francis Hotel. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at  http://www.aethlonmedical.com/news-media/presentations. Aethlon Medical is focused on addressing unmet needs in global health and biodefense.

  • PR Newswire10 days ago

    Aethlon Medical Announces Compliance With Nasdaq Listing Criteria

    SAN DIEGO , Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that Nasdaq has ...

  • PR Newswire18 days ago

    Aethlon Medical Announces Pricing of $6 Million Public Offering

    SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announces the pricing of a public offering of an aggregate of 5,454,546 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • PR Newswirelast month

    Aethlon Medical Receives National Cancer Institute Contract Award

    The NCI Phase I contract period runs from September 15, 2017 and runs through June 14, 2018.  The total amount of the firm fixed price contract is $299,250.  The contract calls for two subcontractors to work with the Company. The subcontractors under Aethlon Medical on the contract are University of Pittsburgh and Massachusetts General Hospital. Aethlon Medical is investigating the potential use of the Aethlon Hemopurifier® to reduce the presence of circulating tumor-derived exosomes (oncosomes), which contribute to cancer progression.  The Hemopurifier® is currently being advanced to treat life-threatening viral infections under an FDA designated Expedited Access Pathway (EAP) program.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Aldeyra Therapeutics and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Shares of both Aldeyra Therapeutics and Aethon Medical both saw big gains on Tuesday with trading volume for both stocks exploding. Aldeyra rose higher ...

  • PR Newswirelast month

    Aethlon Medical Receives Expedited Access Pathway Designation from FDA to Accelerate U.S. Access to the Hemopurifier® as a Treatment for Life-Threatening Viruses

    SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has received an Expedited Access Pathway (EAP) designation from the United States Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® to treat life-threatening viruses. The FDA EAP program was established to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

  • Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?
    Simply Wall St.last month

    Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?

    If you are looking to invest in Aethlon Medical Inc’s (NASDAQ:AEMD), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • PR Newswirelast month

    Aethlon Medical to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017

    SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced that its Chairman and CEO, Jim Joyce, will be a featured presenter at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 11, 2017, at 3:00pm at the Lotte New York Palace Hotel in New York City. The presentation will be live audio webcast through a link available in the upcoming events section of the company's website at http://www.aethlonmedical.com/news-media/presentations.

  • Zacks Small Cap Research2 months ago

    AEMD: EAP Filed, Expect FDA Response By Mid-September

    The major highlight on the operational front since our last update (on June 30th) was submission of the anticipated application to FDA seeking EAP designation for the Hemopurifier.  In an 8-K, filed earlier this week, Aethlon disclosed that they received formal receipt from the FDA of their EAP submission.  Per FDA guidance, the agency’s goal is to make a decision within 30 days (~mid-September) whether to grant EAP designation, or in the event additional information is required, to formally request that the sponsor (i.e.

  • Forbes2 months ago

    Former NFL Pro Supports Study Of Brain Injuries And Dementia In Football

    James Joyce, who played football for the Denver Broncos, is now supporting biotech research aimed at answering questions about the link between repeated head blows and dementia.

  • PR Newswire2 months ago

    Aethlon Medical Announces Fiscal 2018 First Quarter Results

    SAN DIEGO , Aug. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its ...

  • ACCESSWIRE2 months ago

    Investor Network: Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on Thursday, August 10, 2017 at 4:30 PM ...

  • Capital Cube3 months ago

    ETFs with exposure to Aethlon Medical, Inc. : August 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire3 months ago

    Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2018 and Host Conference Call on August 10, 2017

    SAN DIEGO , Aug. 3, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...

  • PR Newswire3 months ago

    Aethlon Medical Announces the Grant of a U.S. Patent Protecting Methods of Capturing MHC Antigen Associated Exosomes

    The '333 Patent covers methods of capturing exosomes that include an MHC-I or MHC-II antigen, whereby a patient suspected of receiving a benefit from exosome capture and removal is selected, and the whole blood, plasma, or serum from the patient is contacted with a substrate that includes antibodies specific for an MHC-I or MHC-II antigen.  The '333 Patent also covers methods of capturing and removing MHC-I or MHC-II antigen associated exosomes from whole blood, plasma, or serum of a patient, and returning the whole blood, plasma, or serum to the patient with substantially fewer MHC-I or MHC-II antigen associated exosomes. MHC-I and MHC-II antigen associated exosomes contribute to the progression of numerous disease conditions, including cancer, autoimmune disorders and neurodegenerative diseases.

  • Accesswire3 months ago

    Corporate News Blog - MedShape Divests its ExoShape(R) ACL Product Line to CONMED

    Research Desk Line-up: Aethlon Medical Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for CONMED ...

  • Capital Cube4 months ago

    ETFs with exposure to Aethlon Medical, Inc. : July 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research4 months ago

    AEMD: Feasibility Study Validates Capture, EAP FDA Filing Is Next

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q4 2017 Financials, Operational Update… Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal fourth quarter 2017 ending March 31st and provided ...

  • Aethlon Medical, Inc. :AEMD-US: Earnings Analysis: 2017 By the Numbers : June 30, 2017
    Capital Cube4 months ago

    Aethlon Medical, Inc. :AEMD-US: Earnings Analysis: 2017 By the Numbers : June 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Aethlon Medical, Inc. reports financial results for the year ended March 31, 2017. Highlights Change in operating cash flow of 19.02% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals or reserves. Narrowing of operating margins contributed to decline in ... Read more (Read more...)

  • PR Newswire4 months ago

    Aethlon Medical Announces Fiscal 2017 Results

    SAN DIEGO , June 28, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its ...

  • PR Newswire4 months ago

    Aethlon Medical To Release 2017 Fiscal Year End Financial Results and Host Conference Call on June 28, 2017

    SAN DIEGO , June 26, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced it will issue financial ...